SOPHIA GENETICS, INC.

Sophia Genetics, Inc. specializes in advanced bioinformatics services for medical laboratories, delivering exome sequencing analysis, genomic data interpretation, and computational pipelines tailored to clinical and defense health applications. Their core expertise lies in processing and analyzing high-throughput genomic datasets using proprietary algorithms and machine learning models to extract clinically actionable insights from complex biological data. The contractor provides end-to-end bioinformatics support—from raw sequence alignment and variant calling to phenotype-genotype correlation—enabling precision diagnostics and research outcomes in military and civilian healthcare environments. Their technical differentiation stems from scalable, validated workflows optimized for large-scale genomic datasets, with proven experience in supporting defense-grade data integrity and regulatory compliance standards. The company maintains a consistent relationship with the Department of Defense and the Defense Health Agency, delivering bioinformatics interpretation and testing services that support military medical readiness, veteran health analytics, and operational genomics. Their work directly enables rapid identification of genetic markers relevant to trauma response, infectious disease surveillance, and personalized treatment protocols within DoD medical systems. Sophia Genetics operates primarily under NAICS 621511, which classifies them as a medical laboratory specializing in molecular diagnostics and genomic analysis. Their market positioning centers on bridging cutting-edge genomic science with operational healthcare delivery, serving a niche but critical segment of defense and public health infrastructure that demands high-accuracy, high-throughput genomic interpretation. As a 2L entity headquartered in Boston, Massachusetts, Sophia Genetics, Inc. is structured as a private, for-profit organization with no disclosed government certifications. Their geographic presence is concentrated in the U.S. biotech corridor, leveraging regional access to academic research hubs and federal health agencies to deliver mission-critical genomic solutions.